Efficacy of three COVID-19 vaccine doses in lung transplant recipients: a multicentre cohort study.
Journal
The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
10
03
2022
accepted:
11
08
2022
pubmed:
21
10
2022
medline:
24
1
2023
entrez:
20
10
2022
Statut:
epublish
Résumé
Do three coronavirus disease 2019 (COVID-19) vaccine doses induce a serological response in lung transplant recipients? We retrospectively included 1071 adults (551 (52%) males) at nine transplant centres in France. Each had received three COVID-19 vaccine doses in 2021, after lung transplantation. An anti-spike protein IgG response, defined as a titre >264 BAU·mL Median (IQR) follow-up after the first dose was 8.3 (6.7-9.3) months. A vaccine response developed in 173 (16%) patients. Factors independently associated with a response were younger age at vaccination, longer time from transplantation to vaccination and absence of corticosteroid or mycophenolate therapy. After vaccination, 51 (5%) patients (47 non-responders (47/898 (5%)) and four (4/173 (2%)) responders) experienced COVID-19, at a median (IQR) of 6.6 (5.1-7.3) months after the third dose. No responders had severe COVID-19 compared with 15 non-responders, including six who died of the disease. Few lung transplant recipients achieved a serological response to three COVID-19 vaccine doses, indicating a need for other protective measures. Older age and use of mycophenolate or corticosteroids were associated with absence of a response. The low incidence of COVID-19 might reflect vaccine protection
Identifiants
pubmed: 36265877
pii: 13993003.00502-2022
doi: 10.1183/13993003.00502-2022
pmc: PMC9644237
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright ©The authors 2023.
Déclaration de conflit d'intérêts
Conflict of interest: None for any authors.
Références
Sci Rep. 2022 Mar 8;12(1):3788
pubmed: 35260713
Lancet Respir Med. 2021 Jun;9(6):e52-e53
pubmed: 33964244
Am J Transplant. 2022 Jan;22(1):322-323
pubmed: 34331842
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
J Heart Lung Transplant. 2021 Dec;40(12):1579-1588
pubmed: 34456108
Kidney Int. 2021 Nov;100(5):1132-1135
pubmed: 34474075
Ann Intern Med. 2021 Sep;174(9):1330-1332
pubmed: 34125572
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
JAMA Netw Open. 2022 May 2;5(5):e2212073
pubmed: 35560054
Int Immunopharmacol. 2021 Nov;100:108095
pubmed: 34619529
Am J Transplant. 2021 Mar;21(3):1295-1303
pubmed: 33259686
N Engl J Med. 2021 Aug 12;385(7):661-662
pubmed: 34161700
Nature. 2021 Sep;597(7875):268-273
pubmed: 34320609
N Engl J Med. 2021 Sep 23;385(13):1244-1246
pubmed: 34379917
Transplantation. 2021 Nov 1;105(11):e267-e269
pubmed: 34342963
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
JAMA. 2021 Jul 23;:
pubmed: 34297036
Transplantation. 2021 May 1;105(5):e52-e53
pubmed: 33617174
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
Clin Infect Dis. 2021 Dec 6;73(11):e4090-e4099
pubmed: 32766815
JAMA. 2021 May 4;325(17):1784-1786
pubmed: 33720292
Lancet Infect Dis. 2022 Aug;22(8):1114-1116
pubmed: 35752196
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Transplantation. 2021 Jan 1;105(1):177-186
pubmed: 33141808
Nature. 2021 Jul;595(7868):572-577
pubmed: 34044428
JAMA. 2021 Jun 1;325(21):2204-2206
pubmed: 33950155